newsfilter
← Latest News
Business Wire·

Prespecified Analysis of ATHOS-3 Indicates Survival Benefit in LJPC-501-Treated Patients with Relatively Low Angiotensin II State

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla) today announced an abstract entitled "Baseline angiotensin levels and ACE effects in patients with vasodilatory shock treated with angiotensin II" has been selected for presentation at the upcoming 30th European Society of Intensive Care Medicine (ESICM) LIVES Annual Congress being held September 23 to 27, 2017 in Vienna, Austria.